Treace Medical (TMCI) director receives 30,000 RSU equity award and updates holdings

Rhea-AI Filing Summary

BAKEWELL JOHN K reported acquisition or exercise transactions in this Form 4 filing.

TREACE MEDICAL CONCEPTS director John K. Bakewell received an equity grant and updated his holdings. He was granted 30,000 restricted stock units, each convertible into one share of common stock, which will vest 100% on the earlier of May 19, 2027 or the 2027 annual stockholder meeting, subject to continued service. Bakewell elected to defer delivery of the shares until a change in control, his separation of service, or the fifth anniversary of the grant date. Following the grant, he holds 204,056 shares directly, including the 30,000 RSUs, and additional indirect holdings of 92,300 shares as trustee of a trust and 250,000 shares held by his spouse as trustee of a trust.

Insights

Equity compensation analyst

Routine RSU grant increases director’s equity stake in TMCI.

Director John K. Bakewell received 30,000 restricted stock units in TREACE MEDICAL CONCEPTS, a typical equity-based compensation award for board service. The grant vests in full in 2027, aligning his compensation with longer-term company performance.

The RSUs vest on the earlier of May 19, 2027 or the 2027 annual stockholder meeting, contingent on his continued service. He elected to defer share delivery until a change in control, separation of service, or five years after the grant, which shifts potential tax and liquidity timing.

After this award, he directly holds 204,056 shares, including the 30,000 RSUs, plus significant indirect holdings through trusts. This filing reflects compensation rather than open-market buying or selling, so it is generally viewed as routine and informational.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider BAKEWELL JOHN K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,000	$0.00	--
holding	Common Sotck	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 204,056 shares (Direct, null); Common Sotck — 250,000 shares (Indirect, By spouse as trustee of a trust); Common Stock — 92,300 shares (Indirect, As trustee of a trust)

Footnotes (1)

1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date. Includes 30,000 restricted stock units.

Key Figures

RSU grant size: 30,000 RSUs RSU vesting date: May 19, 2027 Direct holdings after grant: 204,056 shares +3 more

6 metrics

RSU grant size 30,000 RSUs Equity award to director John K. Bakewell

RSU vesting date May 19, 2027 100% vesting or earlier 2027 annual meeting

Direct holdings after grant 204,056 shares Includes 30,000 RSUs following transaction

Indirect trust holdings 92,300 shares Held as trustee of a trust

Spousal trust holdings 250,000 shares Held by spouse as trustee of a trust

Grant price per RSU $0.0000 per unit RSU award, no purchase price

Key Terms

restricted stock units (RSUs), change in control, separation of service, trustee of a trust, +1 more

5 terms

restricted stock units (RSUs) financial

"Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

change in control financial

"until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

separation of service financial

"until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date."

trustee of a trust financial

"nature_of_ownership: As trustee of a trust"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAKEWELL JOHN K

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA BEACH FLORIDA 32081

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		30,000(1)	A	$0	204,056(2)	D
Common Sotck								250,000	I	By spouse as trustee of a trust
Common Stock								92,300	I	As trustee of a trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date.

2. Includes 30,000 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for John Bakewell	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TMCI director John K. Bakewell acquire in this Form 4 filing?

John K. Bakewell received 30,000 restricted stock units in TMCI as an equity award. Each RSU converts into one share of common stock upon vesting, representing additional stock-based compensation rather than an open-market share purchase.

When do John K. Bakewell’s new TMCI restricted stock units vest?

The 30,000 TMCI restricted stock units vest 100% on the earlier of May 19, 2027 or the 2027 annual meeting. Vesting is conditioned on Bakewell continuing to provide service to Treace Medical Concepts through the applicable vesting date.

How did John K. Bakewell structure receipt of his TMCI RSU shares?

Bakewell elected to defer delivery of TMCI shares issuable from the RSUs. Shares will be delivered on the earlier of a change in control, his separation of service from Treace Medical Concepts, or the fifth anniversary of the RSU grant date.

What are John K. Bakewell’s TMCI share holdings after this transaction?

After the RSU grant, Bakewell directly holds 204,056 TMCI shares, including 30,000 restricted stock units. He also has indirect holdings of 92,300 shares as trustee of a trust and 250,000 shares held by his spouse as trustee of a trust.

Was this TMCI Form 4 a market purchase or sale by John K. Bakewell?

The Form 4 reports an equity award, not a market trade, for John K. Bakewell. He acquired 30,000 restricted stock units in TMCI as compensation, with no open-market buying or selling disclosed in this filing.